In June 2022, the FDA authorized use of two doses of a 100mcg Moderna COVID-19 mRNA vaccine in adolescents 12 through 17 years of age and two doses of a 50mcg Moderna COVID-19 vaccine in children six through 11 years of age under EUA. According to the FDA, the most common adverse events reported after vaccination during clinical trials included injection site redness, pain, and swelling, fever, chills, headache, nausea, vomiting, muscle and joint pain, fatigue, and swollen lymph nodes in the same arm of the injection.
Twelve vaccine recipients aged 12 through 17 years of age experienced cardiovascular symptoms (chest pain, shortness of breath, and palpitations). This included a 12-year-old male who was hospitalized with chest pain, shortness of breath and abnormal EKG, three additional cases of shortness of breath, seven reports of syncope, and one report of palpitations. Forty-nine events of hypersensitivity reactions occurred among 46 vaccine recipients, and reported as injection site rash, hypersensitivity, dermatitis, and urticaria. No cases of anaphylaxis were reported. Additional adverse events included appendicitis, depression/suicidal ideation, drug-induced liver injury, and surgical repair of pectus excavatum.
Adverse events of clinical significance reported among six through 11-year-old children who received the vaccine included epilepsy and seizures, loss of taste and smell, Tourette’s Syndrome, chest pain, shortness of breath, palpitations, musculoskeletal chest pain, vasovagal syncope, upper abdominal pain, suicidal ideation, oppositional defiant disorder, disruptive mood disorder, gastrointestinal disorder, asthma, synovitis, neck pain, epiphyseal fracture, Kawasaki Disease, ileus, and bradycardia.